Business Context and Reporting Period
AVITA Medical, Inc. filed a Form 8-K dated June 15, 2023, under Items 5.02, 7.01, and 9.01. The filing announces David O’Toole’s appointment as Chief Financial Officer, effective June 15, 2023. The company develops and commercializes regenerative medicine products.
Financial Metrics and Liquidity
This filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other operating financial metrics.
Material Changes Versus the Prior Comparable Period
- David O’Toole replaced the prior CFO role holder; the filing does not identify the predecessor or provide transition details.
- O’Toole brings more than 30 years of corporate finance, capital markets, accounting, and life sciences experience, most recently serving as CFO of Opiant Pharmaceuticals until its acquisition by Indivior PLC in March 2023.
Compensation, Outlook, and Other Considerations
- Annual base salary: $450,000, subject to annual Board review.
- Annual performance bonus target: 40% of base salary, with potential for an additional amount of up to 50% of the annual bonus at the Board’s discretion. For 2023, the bonus is prorated based on salary earned during the year and remains subject to performance and continued employment conditions.
- Subject to Board approval, O’Toole will receive 150,000 stock options under the 2020 Omnibus Incentive Plan, vesting in three equal annual installments beginning after his first year of service.
- The agreement is at-will and has no specified term.
- If terminated without Cause or if O’Toole resigns for Good Reason, the company will provide 12 months of base salary, 12 months of health benefits, and acceleration of unvested options, which will remain exercisable for three months.
- The agreement includes noncompetition and employee and customer nonsolicitation covenants.
- The filing contains no financial guidance or broader business outlook. The employment agreement’s full text is expected to be filed as an exhibit to the company’s Form 10-Q for the quarter ended June 30, 2023.
Key Facts to Verify
- Confirm Board approval, grant date, exercise price, and detailed terms of the 150,000 stock options.
- Review the complete employment agreement when filed with the Form 10-Q.
- Confirm the identity and circumstances of the prior CFO’s departure, which are not clearly provided in this filing.
- Assess the potential annual compensation cost, including the base salary, performance bonus, severance exposure, benefits, and equity award.